Opinion

Video

Patient Selection and Switching Patients to Subcutaneous Infliximab

Author(s):

Jean-Frederic Colombel, MD

Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.

  1. For patients currently receiving IV infliximab (originator or biosimilar), are there any considerations for switching them to subcutaneous infliximab?
  2. How will subcutaneous infliximab fit in with the growing IBD treatment landscape?
Related Videos
Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD
Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
Investigating Brensocatib, Potential First Treatment for Bronchiectasis, with James Chalmers, MBChB, PhD
Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
AI in Dermatology: Emerging Insights and Diverging Perspectives
Related Content
Patch Test Highlights Allergens Impacting Alopecia Areata, Other Hair Conditions
February 21st 2025

Patch Test Highlights Allergens Impacting Alopecia Areata, Other Hair Conditions

Tim Smith
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
February 15th 2025

Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Approves Chenodiol Tablets for Cerebrotendinous Xanthomatosis | Image Credit: US Food and Drug Administration
February 21st 2025

FDA Approves Chenodiol Tablets for Cerebrotendinous Xanthomatosis

Connor Iapoce
Kidney Compass: Navigating Clinical Trials
February 13th 2025

Kidney Compass: Applying Hierarchical Composite Endpoints in Kidney Disease Trials

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
FDA Announces End to Shortage of Semaglutide Products (Ozempic, Wegovy) | Image Credit: US Food and Drug Administration
February 21st 2025

FDA Announces End to Shortage of Semaglutide Products (Ozempic, Wegovy)

Connor Iapoce
New Biosimilar, Ustekinumab-aekn, Now Available in U.S.
February 21st 2025

New Biosimilar, Ustekinumab-aekn, Now Available in U.S.

Victoria Johnson
© 2025 MJH Life Sciences

All rights reserved.